We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.
- Authors
Hsu, David S; Balakumaran, Bala S; Acharya, Chaitanya R; Vlahovic, Vanja; Walters, Kelli S; Garman, Katherine; Anders, Carey; Riedel, Richard F; Lancaster, Johnathan; Harpole, David; Dressman, Holly K; Nevins, Joseph R; Febbo, Phillip G; Potti, Anil
- Abstract
Standard treatment for advanced non-small-cell lung cancer (NSCLC) includes the use of a platinum-based chemotherapy regimen. However, response rates are highly variable. Newer agents, such as pemetrexed, have shown significant activity as second-line therapy and are currently being evaluated in the front-line setting. We utilized a genomic strategy to develop signatures predictive of chemotherapeutic response to both cisplatin and pemetrexed to provide a rational approach to effective individualized medicine.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Vol 25, Issue 28, p4350
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.11.0593